Cargando…
Selenofolate inhibits the proliferation of IGROV1 cancer cells independently from folate receptor alpha
Cancer is one of the main causes of human mortality worldwide and novel chemotherapeutics are required due to the limitations of conventional cancer therapies. For example, using redox selenium compounds as novel chemotherapeutics seem to be very promising. The objective of this study was to explore...
Autores principales: | Razaghi, Ali, Zickler, Antje Maria, Spallholz, Julian, Kirsch, Gilbert, Björnstedt, Mikael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8209087/ https://www.ncbi.nlm.nih.gov/pubmed/34169173 http://dx.doi.org/10.1016/j.heliyon.2021.e07254 |
Ejemplares similares
-
Redox-Active Selenium Compounds—From Toxicity and Cell Death to Cancer Treatment
por: Misra, Sougat, et al.
Publicado: (2015) -
Betacoronaviruses SARS-CoV-2 and HCoV-OC43 infections in IGROV-1 cell line require aryl hydrocarbon receptor
por: Yousefi, Meisam, et al.
Publicado: (2023) -
Isolation and characterization of an IGROV-1 human ovarian cancer cell line made resistant to Ecteinascidin-743 (ET-743)
por: Erba, E, et al.
Publicado: (2000) -
Copy number alteration of the interferon gene cluster in cancer: Individual patient data meta-analysis prospects to personalized immunotherapy
por: Razaghi, Ali, et al.
Publicado: (2021) -
Combining PD-1/PD-L1 blockade with type I interferon in cancer therapy
por: Razaghi, Ali, et al.
Publicado: (2023)